Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) - Meet-URO

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

Autore

Alessia Mennitto

Patologia

Rene

Rivista

European Journal of Cancer

Anno

2021

DOI

https://doi.org/10.1080/14737140.2022.2002688

Studio di riferimento